全文获取类型
收费全文 | 394篇 |
免费 | 24篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 12篇 |
基础医学 | 43篇 |
临床医学 | 55篇 |
内科学 | 172篇 |
皮肤病学 | 1篇 |
神经病学 | 45篇 |
特种医学 | 33篇 |
外科学 | 15篇 |
综合类 | 3篇 |
预防医学 | 20篇 |
药学 | 11篇 |
肿瘤学 | 9篇 |
出版年
2022年 | 3篇 |
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 8篇 |
2017年 | 2篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 15篇 |
2013年 | 14篇 |
2012年 | 36篇 |
2011年 | 29篇 |
2010年 | 21篇 |
2009年 | 12篇 |
2008年 | 42篇 |
2007年 | 39篇 |
2006年 | 25篇 |
2005年 | 19篇 |
2004年 | 20篇 |
2003年 | 19篇 |
2002年 | 15篇 |
2001年 | 10篇 |
2000年 | 8篇 |
1999年 | 8篇 |
1998年 | 3篇 |
1997年 | 5篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1991年 | 2篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1983年 | 1篇 |
1981年 | 1篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1972年 | 1篇 |
1964年 | 2篇 |
1963年 | 2篇 |
排序方式: 共有419条查询结果,搜索用时 220 毫秒
41.
42.
Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion 总被引:6,自引:1,他引:6 下载免费PDF全文
Schäfer A Schulz C Eigenthaler M Fraccarollo D Kobsar A Gawaz M Ertl G Walter U Bauersachs J 《Blood》2004,103(2):407-412
Chemokines released by the endothelium have proaggregatory properties on platelets. Fractalkine, a recently discovered membrane-bound chemokine with a transmembrane domain, is expressed in vascular injury; however, the effects of fractalkine on platelets have not yet been investigated. Blood was taken from healthy Wistar-Kyoto rats and the expression of the fractalkine receptor on platelets was demonstrated. The modulation of surface expression of P-selectin was assessed by flow cytometry. P-selectin expression was significantly enhanced by in vitro stimulation with recombinant rat fractalkine compared with baseline levels. Selectively inhibiting the function of recombinant fractalkine by an antagonizing antibody or the disruption of the G-protein-coupled intracellular signaling cascade of the fractalkine receptor by pertussis toxin (PTX) completely prevented fractalkine-mediated platelet activation. Preincubation with apyrase significantly attenuated the fractalkine-induced degranulation. In a flow chamber model of platelet adhesion, stimulation with fractalkine significantly enhanced platelet adhesion to collagen and fibrinogen. Similar to P-selectin expression, enhanced adhesion could be prevented by the antagonizing antibody or preincubation of platelets with PTX. Fractalkine, which is overexpressed in atherosclerosis and vascular injury, contributes to platelet activation and adhesion and hence is likely to play a pathophysiologically important role for increased thrombogenesis in vascular diseases. 相似文献
43.
Langer HF Haubner R Pichler BJ Gawaz M 《Journal of the American College of Cardiology》2008,52(1):1-12
Despite primary and secondary prevention, serious cardiovascular events such as unstable angina or myocardial infarction still account for one-third of all deaths worldwide. Therefore, identifying individual patients with vulnerable plaques at high risk for plaque rupture is a central challenge in cardiovascular medicine. Several noninvasive techniques, such as magnetic resonance imaging, multislice computed tomography, and electron beam tomography are currently being tested for their ability to identify such patients by morphological criteria. In contrast, molecular imaging techniques use radiolabeled molecules to detect functional aspects in atherosclerotic plaques by visualizing their biological activity. Based upon the knowledge about the pathophysiology of atherosclerosis, various studies in vitro and in vivo and the first clinical trials have used different tracers for plaque imaging studies, including radioactive-labeled lipoproteins, components of the coagulation system, cytokines, mediators of the metalloproteinase system, cell adhesion receptors, and even whole cells. This review gives an update on the relevant noninvasive plaque imaging approaches using nuclear imaging techniques to detect atherosclerotic vascular lesions. 相似文献
44.
45.
46.
47.
Gawaz M Brand K Dickfeld T Pogatsa-Murray G Page S Bogner C Koch W Schömig A Neumann F 《Atherosclerosis》2000,148(1):75-85
48.
49.
Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting 总被引:2,自引:0,他引:2
Neumann FJ Hochholzer W Pogatsa-Murray G Schömig A Gawaz M 《Journal of the American College of Cardiology》2001,37(5):1323-1328
OBJECTIVES: We sought to investigate whether abciximab, tirofiban and eptifibatide achieve comparable antiplatelet effects with coronary stenting. BACKGROUND: The glycoprotein (GP) IIb/IIIa antagonists abciximab, tirofiban and eptifibatide differ in chemical structure, binding site and pharmacokinetics. METHODS: Sixty patients undergoing coronary stenting were randomly assigned to abciximab (bolus 0.25 mg/kg body weight, infusion 10 microg per min for 12 h), tirofiban (bolus 10 microg/kg, infusion 0.15 microg/kg per min for 72 h) or eptifibatide (bolus 180 microg/kg, infusion 2 microg/kg per min for 72 h). We took serial blood samples to analyze platelet function by using flow cytometry, turbidimetric aggregometry and the rapid platelet-function assay (RPFA). RESULTS: As assessed by RPFA, platelet aggregation after 2 h of infusion was reduced to 5.9 +/- 7.8% (mean +/- SD) of baseline by abciximab, to 5.0 +/- 5.4% by tirofiban and to 7.8 +/- 7.1% by eptifibatide (p = 0.42). Turbidimetric aggregometry with adenosine diphosphate stimulation yielded similar results, whereas percent inhibition of platelet aggregation after thrombin receptor stimulation was 45.8 +/- 16.8% with abciximab, 51.3 +/- 17.6% with tirofiban and 52.9 +/- 14.8% with eptifibatide (p = 0.37). Tirofiban and eptifibatide maintained their level of platelet inhibition during infusion. Flow cytometry revealed that the reduction in the monocyte-platelet interaction by abciximab, tirofiban and eptifibatide was not significantly different (20.0 +/- 21.9%, 23.8 +/- 18.2% and 21.0 +/- 19.8%, respectively; p = 0.87). CONCLUSIONS: Abciximab, tirofiban and eptifibatide, at currently recommended doses, achieved similar levels of inhibition of platelet aggregation and a similar reduction in the platelet-monocyte interaction. 相似文献